longeveron llc is a leading global regenerative medicine company developing innovative cellular therapeutics for chronic life-threatening diseases. our lead investigational product candidate (lmsc) is based on a specialized cell known as a mesenchymal stem cell that is derived from the bone marrow of healthy young adult donors. our allogeneic, ‘off-the-shelf’ product is under investigation for chronic conditions of the elderly, and other life- threatening diseases, for which no approved therapeutics currently exist: • aging frailty syndrome • alzheimer’s disease • hypoplastic left heart syndrome • the metabolic syndrome
Company profile
Ticker
LGVN
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
LONGEVERON LLC
SEC CIK
Corporate docs
IRS number
472174146
LGVN stock data
Latest filings (excl ownership)
8-K
Longeveron Announces Exercise of Warrants for $6.2 Million Gross Proceeds
18 Apr 24
EFFECT
Notice of effectiveness
18 Apr 24
424B4
Prospectus supplement with pricing info
17 Apr 24
S-1/A
IPO registration (amended)
16 Apr 24
8-K
Longeveron Announces Pricing of $5.25 Million Public Offering
11 Apr 24
424B3
Prospectus supplement
10 Apr 24
424B4
Prospectus supplement with pricing info
10 Apr 24
EFFECT
Notice of effectiveness
9 Apr 24
FWP
Free writing prospectus
8 Apr 24
S-1/A
IPO registration (amended)
5 Apr 24
Transcripts
LGVN
Earnings call transcript
2023 Q3
10 Nov 23
LGVN
Earnings call transcript
2023 Q2
11 Aug 23
LGVN
Earnings call transcript
2023 Q1
12 May 23
LGVN
Earnings call transcript
2022 Q4
10 Mar 23
LGVN
Earnings call transcript
2022 Q3
14 Nov 22
LGVN
Earnings call transcript
2022 Q2
14 Aug 22
LGVN
Earnings call transcript
2022 Q1
17 May 22
LGVN
Earnings call transcript
2021 Q4
11 Mar 22
LGVN
Earnings call transcript
2021 Q3
12 Nov 21
LGVN
Earnings call transcript
2021 Q2
14 Aug 21
Latest ownership filings
SC 13G
INTRACOASTAL CAPITAL, LLC
17 Apr 24
SC 13D/A
Hare Joshua
15 Apr 24
4
Joshua Hare
12 Apr 24
4
Mohamed Wa'el Ahmed Hashad
12 Apr 24
4
Rock Soffer
12 Apr 24
4
Mohamed Wa'el Ahmed Hashad
20 Mar 24
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
4
Mohamed Wa'el Ahmed Hashad
2 Feb 24
4
Lisa Locklear
25 Jan 24
4
Mohamed Wa'el Ahmed Hashad
25 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.97 mm | 1.97 mm | 1.97 mm | 1.97 mm | 1.97 mm | 1.97 mm |
Cash burn (monthly) | 260.00 k | 967.25 k | 1.72 mm | 1.74 mm | 1.52 mm | 1.44 mm |
Cash used (since last report) | 1.78 mm | 6.63 mm | 11.78 mm | 11.89 mm | 10.40 mm | 9.88 mm |
Cash remaining | 186.00 k | -4.66 mm | -9.82 mm | -9.92 mm | -8.44 mm | -7.92 mm |
Runway (months of cash) | 0.7 | -4.8 | -5.7 | -5.7 | -5.6 | -5.5 |
Institutional ownership, Q3 2023
17.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 19 |
Opened positions | 5 |
Closed positions | 7 |
Increased positions | 2 |
Reduced positions | 6 |
13F shares | Current |
---|---|
Total value | 1.37 bn |
Total shares | 585.44 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 183.21 k | $428.70 mm |
BLK Blackrock | 111.84 k | $261.70 mm |
Creative Planning | 109.32 k | $255.81 mm |
Geode Capital Management | 73.47 k | $170.48 mm |
Millennium Management | 20.42 k | $47.38 mm |
STT State Street | 14.80 k | $34.34 mm |
Townsquare Capital | 14.45 k | $33.81 mm |
Lloyd Advisory Services | 14.45 k | $33.81 mm |
Norden | 14.45 k | $33.81 mm |
Schonfeld Strategic Advisors | 12.80 k | $29.95 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Apr 24 | Mohamed Wa'el Ahmed Hashad | Class A Common Stock | Buy | Acquire P | No | No | 2.35 | 10,638 | 25.00 k | 19,616 |
11 Apr 24 | Mohamed Wa'el Ahmed Hashad | Warrant Class A Common Stock | Buy | Acquire P | No | No | 0.125 | 10,638 | 1.33 k | 10,638 |
11 Apr 24 | Joshua Hare | Class A Common Stock | Buy | Acquire P | No | No | 2.35 | 42,553 | 100.00 k | 633,280 |
11 Apr 24 | Joshua Hare | Warrant Class A Common Stock | Buy | Acquire P | No | No | 0.125 | 42,553 | 5.32 k | 42,553 |
11 Apr 24 | Rock Soffer | Class A Common Stock | Buy | Acquire P | No | No | 2.35 | 31,915 | 75.00 k | 208,534 |
11 Apr 24 | Rock Soffer | Warrant Class A Common Stock | Buy | Acquire P | No | No | 0.125 | 31,915 | 3.99 k | 31,915 |
10 Apr 24 | Joshua Hare | Class A Common Stock | Buy | Acquire P | No | No | 2.35 | 106,383 | 250.00 k | 590,727 |
10 Apr 24 | Joshua Hare | Warrant Class A Common Stock | Buy | Acquire P | No | No | 0.125 | 106,383 | 13.30 k | 106,383 |
10 Apr 24 | Rock Soffer | Class A Common Stock | Buy | Acquire P | No | No | 2.35 | 106,383 | 250.00 k | 176,619 |
10 Apr 24 | Rock Soffer | Warrant Class A Common Stock | Buy | Acquire P | No | No | 0.125 | 106,383 | 13.30 k | 106,383 |
News
Longeveron Raises A Total Of $11.4M In Gross Proceeds From Warrant Exercise Offering And Public Offering
18 Apr 24
Peering Into Longeveron's Recent Short Interest
18 Apr 24
Crude Oil Dips 3%; U.S. Bancorp Profit Tops Views
17 Apr 24
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
17 Apr 24
Nasdaq Down Over 1%; Sage Therapeutics Shares Plunge
17 Apr 24
Press releases
Longeveron's CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B™ in Mild Alzheimer's Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer's Association International Conference (AAIC)
15 Apr 24
Longeveron Announces Closing of $5.2 Million Public Offering
11 Apr 24
Longeveron Announces Pricing of $5.25 Million Public Offering
8 Apr 24
Longeveron Issues Letter to Shareholders Highlighting Corporate Strategy, Clinical Pipeline and 2024 Key Priorities and Goals
8 Apr 24
Longeveron (NASDAQ: LGVN) Making Inroads With Lomecel-B™ – Biotech's Investigational Alzheimer's Treatment Shows Positive Trial Results
8 Feb 24